1stOncology™: Cancer Intelligence Service – Page 9851 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Acacia Pharma to Report its Results for the Full Year 2020 and Provide a Business Update on 29 March 2021

On March 18, 2021 Acacia Pharma Group plc ("Acacia Pharma" or the "Company") (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy, reported that it will report its results for the full year 2020 and provide an update on progress with the commercialization of BARHEMSYS and BYFAVO on Monday, 29 March 2021 at 07.00 CEST (Press release, Acacia Pharma, MAR 18, 2021, View Source [SID1234576841]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

A presentation by Acacia Pharma’s senior management team will be webcast live the same day at 14.30 CEST (08.30 EST).

The webcast can be accessed from www.acaciapharma.com and a recording will be available after the event.

The results report and presentation will be available at www.acaciapharma.com in the Investors section from 07.00 CEST the same day.

FUJIFILM Cellular Dynamics and Sana Biotechnology Announce License Agreement for the Development of iPSC-Derived Cell Therapies

On March 17, 2021 FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC) technologies, and Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, reported that Sana has been granted a non-exclusive right to use FUJIFILM Cellular Dynamics’ iPSC platform for the development of commercial cell therapies (Press release, Sana Biotechnology, MAR 17, 2021, View Source [SID1234584002]). As a treatment modality, cell therapies have the potential to augment, repair, or replace human biology, including organs, tissues and cells.

Under the agreement, FUJIFILM Cellular Dynamics grants Sana a non-exclusive license under intellectual property rights owned or controlled by FUJIFILM Cellular Dynamics, and will provide iPSC cell lines (including research-grade and/or Good Manufacturing Practices (GMP)-grade iPSC lines) to Sana. Sana may use the iPSC cell lines, and exercise the licensed intellectual property rights, for the research and development, and with respect to GMP-grade cell lines, clinical and commercial manufacture, and commercialization, of cell therapies derived from such lines. Terms of the agreement were not disclosed.

"FUJIFILM Cellular Dynamics is a leading global player in the field of iPSCs. Our history in manufacturing iPSCs for research-purposes has provided us with the foundational expertise to manufacture quality GMP-grade iPSC lines," said Takeshi Yamamoto, chief executive officer, FUJIFILM Cellular Dynamics. "Sana is developing a broad and compelling pipeline of iPSC-derived cellular therapies, and we are pleased to grant them the rights to our iPSC platform with a vision of providing more treatment options for patients."

"Sana is committed to the development of engineered cells as medicines that can be manufactured at scale and supplied to patients globally," said Stacey Ma, executive vice president, technical operations, Sana. "FUJIFILM Cellular Dynamics is a long-standing innovative leader in this field, and we are thrilled to have the opportunity to combine their expertise in GMP-grade iPSC cell lines with our investment in differentiating and manufacturing cells at scale for patients across a number of diseases."

Panbela Schedules Conference Call on March 25, 2021 to Report 2020 Fourth Quarter Financial Results

On March 17, 2021 Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer reported that it will host a conference call on March 25, 2021 at 4:30 PM Eastern Time to discuss results for its fourth quarter ended December 31, 2020 (Press release, Panbela Therapeutics, MAR 17, 2021, View Source [SID1234583754]).

Conference Call Information

To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.

About SBP-101

SBP-101 is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumors. The molecule has shown signals of tumor growth inhibition in clinical studies of US and Australian metastatic pancreatic cancer patients, suggesting potential complementary activity with an existing FDA-approved standard chemotherapy regimen. In data evaluated from clinical studies to date, SBP-101 has not shown exacerbation of bone marrow suppression and peripheral neuropathy, which can be chemotherapy-related adverse events. Recently observed serious visual adverse events are being evaluated and the FDA has issued a partial clinical hold for the impacted study, pending Panbela’s evaluation and response. The safety data and PMI profile observed in the current Panbela sponsored clinical trial generally provides potential support for continued evaluation of the compound in a randomized clinical trial, subject to Panbela’s submission of a complete response and the FDA’s removal of the partial clinical hold. For more information, please visit View Source

Pipeline MiCheck® Pancreatic Cancer Diagnostic — Positive Results

On March 17, 2021 Minomic reported that positive results from our collaborative research evaluating Minomic’s GPC-1 antibody for the detection of pancreatic cancer (one of the deadliest cancers) in collaboration with BARD1 Life Sciences Ltd EXO-NET exosome capture technology (Press release, Minomic, MAR 17, 2021, View Source [SID1234577225]).

Minomic’s GPC-1 antibody specifically binds EXO-NET isolated exosomes from pancreatic cancer but not healthy exosomes demonstrating a feasible approach for pancreatic cancer detection. You can read the ASX release from BARD1 here: View Source

We continue with the roll-out of our MiCheck Prostate test in Australia having piloted patient testing at Macquarie University Hospital Urology Clinic. We are also well progressed with our US roll-out plans.

Jamie Foxx, Stand Up To Cancer And Exact Sciences Launch PSA To Increase Awareness Of Colorectal Cancer

On March 17, 2021 Academy Award winner Jamie Foxx has joined Stand Up To Cancer (SU2C) and Exact Sciences for a new public service announcement (PSA), reported that which raises awareness about colorectal cancer screenings, early detection and prevention, and focuses on reaching underrepresented communities (Press release, Exact Sciences, MAR 17, 2021, View Source [SID1234577020]). The campaign launched today to coincide with Colorectal Cancer Awareness Month and is in both English and Spanish. The PSA will be placed across print, broadcast, radio, digital and out-of-home outlets.

"Cancer affects everyone. I’ve lost good friends – young friends – to this deadly disease," said Foxx. "We need to make sure that we are taking care of our bodies, paying attention to certain things, that you didn’t necessarily think about when you were younger. Medical issues come up and you may not know what’s at your disposal, so that is why I am proud to shine a light on the importance of getting screened for colon cancer early and bring awareness to the options that are available with this PSA campaign."

In 2020, nearly 148,000 Americans received a new diagnosis of colon or rectal cancer. Black people have the highest colorectal cancer rates of any ethnic group in the United States. They are 20% more likely to get colorectal cancer and 40% more likely to die from it than any other population. And research has shown that colorectal cancer screening rates are the lowest in Hispanic communities, with Black and Hispanic people typically being diagnosed at a later stage in the disease when it is more difficult to treat.

"We are so thankful to Jamie Foxx for lending his voice to this campaign. We have seen a sharp drop in screenings as a result of COVID-19, and this compounds an already significant screening disparity in minority communities," said Sung Poblete, PhD, RN, CEO of Stand Up To Cancer. "With routine screening, colorectal cancer is one of the most preventable cancers. It’s beatable in 90% of cases when detected early, and lives can be saved with just one simple step. People must get screened!"

"We are thrilled to partner with Jamie Foxx and our friends at Stand Up To Cancer to get more people thinking about their options for colorectal cancer screening," said Kevin Conroy, chairman and CEO of Exact Sciences. "We remain committed to addressing the challenges we face in colorectal cancer screening and helping to save lives with education, awareness and cutting-edge research. Providing personalized outreach and making it easier to get people screened is vital, especially in minority communities."

The PSA campaign is part of a larger initiative between Exact Sciences and SU2C. With a $10 million grant from Exact Sciences, SU2C will launch a new colorectal cancer ‘Dream Team’ of researchers that will identify communities near anchor institutions serving medically underserved communities. This Dream Team will help pinpoint unique local needs of those areas and will provide free colorectal cancer testing in the identified zones and study samples collected via approved tests for colorectal cancer, including colonoscopy, CT colonography, flexible sigmoidoscopy, and at-home stool tests that analyze fecal DNA and/or blood. The research will aim to develop better approaches to colorectal cancer interception.

The PSA was directed by Tommy Walker and photographed by G.L. Askew II for Petrol Advertising, a creative marketing and advertising agency specializing in gaming, sports, technology and philanthropy. Walker co-directed and produced the feature-length documentary, God Grew Tired of Us, which won Best Documentary and Audience Award at the 2006 Sundance Film Festival and produced the 2019 documentary, Toni Morrison: The Pieces I Am. Askew, originally from Atlanta, is an artist whose work is rooted in communicating the truth of the human experience.